Maven Health and NeoSens awarded to develop their technologies

Maven Health revolutionises the prevention and screening of metabolic diseases

Maven Health aims to revolutionise the prevention and screening of metabolic diseases, which represent a significant burden for the Swiss healthcare system. Using advanced spectroscopy technology, combined with a proprietary software platform and machine learning algorithms, Maven Health is developing a non-invasive saliva screening solution. This approach enables a comprehensive assessment of metabolic health with increased accuracy, while being less invasive and providing more actionable insights than traditional methods.

The project has the potential to radically transform the way healthcare professionals manage metabolic health, offering a more holistic and proactive solution. Maven Health has been awarded a CHF 100,000 FIT Innogrant. In 2022, Maven Health received an Ignition Grant.

Diagnosing neonatal sepsis with NeoSens

Second project to emerge from EPFL, NeoSens has designed a device to significantly improve the early diagnosis of neonatal sepsis in low- and middle-income countries. By combining artificial intelligence and biosensing technology, NeoSens offers rapid, accurate and cost-effective diagnosis. This technology represents a major advance in the fight against antibiotic resistance and the reduction of healthcare costs associated with neonatal sepsis.

NeoSens, which has already taken part in the EPFL startup acclerator blaze in 2023, has been awarded a CHF 100,000 FIT Innogrant.